116. Which gene is often been inserted in an adenoviral vector to treat cancer by suicidegene
therapy?
(a) GM-CSF,
(b) HSV-TK,
(c) IL-2,
(d) VSV-G

---

Gene Therapy for Cancer: The Role of Suicide Gene Therapy Using HSV-TK

Gene therapy is a promising approach for treating various types of cancer. Among the various strategies, suicide gene therapy is a powerful technique that involves inserting a specific gene into cancer cells to make them self-destructive. One of the most commonly used genes in this therapy is HSV-TK (Herpes Simplex Virus Thymidine Kinase). Let’s delve into how HSV-TK is used in adenoviral vectors for cancer treatment.

What is Suicide Gene Therapy?

Suicide gene therapy involves the introduction of a gene that encodes a protein capable of converting non-toxic prodrugs into toxic metabolites. The idea is to selectively kill cancer cells by activating a toxic substance specifically in those cells, while sparing normal cells. One of the most widely studied suicide genes is HSV-TK.

The Role of HSV-TK in Suicide Gene Therapy

The HSV-TK gene is derived from the herpes simplex virus. When this gene is introduced into cancer cells, the cells are able to express the HSV-TK enzyme. This enzyme converts a harmless drug called ganciclovir into a toxic compound, which interferes with DNA replication and ultimately causes cell death.

In the context of gene therapy, the HSV-TK gene is often delivered into cancer cells using a viral vector, such as an adenoviral vector. This method ensures that the gene reaches the target cells efficiently. Once the HSV-TK gene is inside the cancer cells, the patients are administered ganciclovir, which then activates the gene, leading to the destruction of the tumor cells.

The Correct Answer:

The gene that is often inserted in an adenoviral vector to treat cancer by suicide gene therapy is: (b) HSV-TK.

Why HSV-TK?

1. Specificity: HSV-TK is highly effective because it only activates the prodrug (ganciclovir) in the tumor cells, leading to selective killing of the cancer cells.

2. Safety: HSV-TK is not naturally present in human cells, so it does not affect normal tissues, making it a safe option for targeted therapy.

3. Effective Cancer Treatment: When combined with ganciclovir, HSV-TK-mediated suicide gene therapy has been shown to reduce tumor size and even improve patient survival in various types of cancer, including glioblastoma and melanoma.

Other Genes in Gene Therapy:

While HSV-TK is widely used, other genes are also considered for use in gene therapy for cancer treatment. These include:

1. GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor): This gene is involved in enhancing the immune response by stimulating the production of white blood cells. It’s not typically used for suicide gene therapy but can be part of immunotherapy strategies.

2. IL-2 (Interleukin-2): IL-2 is a cytokine that promotes the growth and activity of T cells, which are crucial for immune responses against cancer. It is often used in immunotherapy but not for suicide gene therapy.

3. VSV-G (Vesicular Stomatitis Virus G protein): VSV-G is a protein that facilitates viral entry into cells and is used in the development of viral vectors, but it does not directly play a role in suicide gene therapy.

Conclusion:

Suicide gene therapy using HSV-TK is a promising approach in cancer treatment, particularly when delivered via adenoviral vectors. This technique allows for targeted cancer cell destruction, minimizing damage to healthy tissues and improving the effectiveness of cancer treatments. As research progresses, the use of suicide gene therapy continues to be explored in combination with other therapies to enhance cancer treatment outcomes.